NKGen Biotech

NKGen Biotech EBIT Margin

The EBIT Margin (Operating Margin) of NKGen Biotech (NKGN) as of Nov 22, 2026 is -31,618.18 %. In the previous year, EBIT Margin (Operating Margin) was -5,131.69 % — a change of 516.14% (lower).

EBIT Margin

-31,618.18 %

YoY

516.14%

Last updated:

EBIT Margin (Operating Margin) of NKGen Biotech is 2022 -31,618.18 % . EBIT Margin (Operating Margin) of NKGen Biotech was 2021 -5,131.69 % . It decreases by 516.14% lower compared to the previous year.

NKGen Biotech's operating (EBIT) margin stands at -31,618.2%, down from -5,131.7% several years earlier.

The NKGen Biotech EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2021
-5,131.69 USD
Jan 1, 2022
-31,618.18 USD
The NKGen Biotech EBIT Margin history
YEAREBIT MarginYoY
-31,618.18 %+516.14%
-5,131.69 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

EBIT Margin (Operating Margin) of NKGen Biotech is -31,618.18 % in 2022.

EBIT Margin (Operating Margin) of NKGen Biotech changed from -5,131.69 % to -31,618.18 %, representing a 516.14% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s NKGen Biotech with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — NKGen Biotech

All Key Metrics — NKGen Biotech